Intelligence · Clinical Pipeline
Regeneron Ireland Designated Pipeline
All ClinicalTrials.gov programs at Regeneron Ireland Designated — phase, modality, and trial IDs.
- Programs
- 10
Quick answer
Regeneron Ireland Designated has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Autologous (self) mononuclear cells derived from umbilical cord blood
Regeneron Ireland Designated Activity Company (DAC)
Hypoplastic Left Heart Syndrome
1 trial -
Autologous Bone Marrow-derived Mononuclear Cells
Regeneron Ireland Designated Activity Company (DAC)
Congenital Heart Disease
1 trial -
Autologous mononuclear cells
Regeneron Ireland Designated Activity Company (DAC)
Congenital Heart Disease, SRV Dependent
1 trial -
Extracellular Vesicles from Mesenchymal Stem Cells
Regeneron Ireland Designated Activity Company (DAC)
COVID-19 Pneumonia
1 trial -
MSC-derived exosomes
Regeneron Ireland Designated Activity Company (DAC)
Long COVID-19 Syndrome
1 trial -
autologous cell-based delivery
Regeneron Ireland Designated Activity Company (DAC)
Hypoplastic Left Heart Syndrome
1 trial -
Cellular Matrix / A-CP-HA Kit
Regeneron Ireland Designated Activity Company (DAC)
Genitourinary Syndrome of Menopause
1 trial -
hyaluronic Acid + platelet-rich plasma
Regeneron Ireland Designated Activity Company (DAC)
Knee Osteoarthritis
1 trial -
Placebo
Regeneron Ireland Designated Activity Company (DAC)
Knee Osteoarthritis
1 trial -
Regen Matrix-PRP-XLHA
Regeneron Ireland Designated Activity Company (DAC)
Knee Osteoarthritis
1 trial
Frequently asked questions
How many pipeline programs does Regeneron Ireland Designated have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs